// App-Quantinova.ai

9036 : Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.

Researchers

Presenter

  • Claire F. Verschraegen

Principal Investigators

  • Franklin Chen

  • David R. Spigel

  • Nicholas Iannotti

  • Edward Francis McClay

  • Charles H. Redfern

  • Jaafar Bennouna

  • Matthew H. Taylor

  • Howard Kaufman

  • Karen Kelly

  • Marcis Bajars

  • Anja von Heydebreck

  • Jean-Marie Cuillerot

  • Guy Heinrich Maria Jerusalem

Medical Centers

  • University of Vermont, Burlington, VT

  • Novant Health Oncology Specialists, Winston-Salem, NC

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, FL

  • California Cancer Care Associates for Research and Excellence, Encinitas, CA

  • Sharp HealthCare, San Diego, CA

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • UC Davis Comprehensive Cancer Center, Sacramento, CA

  • EMD Serono, Inc, Billerica, MA

  • Merck KGaA, Darmstadt, Germany

  • EMD Serono, Inc, Billerica, MA

  • CHU Sart-Tilman Liege and Liege University, Liege, Belgium

Locations

  • United States

  • Germany

  • France

  • Belgium

Companies

  • EMD Serono Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Epidermal growth factor receptor

Drug/Treatment

  • Avelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01772004

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved